Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1807-1813

  West, Howard L ^b   Franklin, Wilbur A ^b   McCoy, Jason ^b   Gumerlock, Paul H ^b   Vance, Ralph ^b   Lau, Derick H M ^b   Chansky, Kari ^b   Crowley, John J ^b   Gandara, David R ^b   Granados, Bonnie ^a  

^a Southwest Oncology Group   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33646381931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.9890     Document Type: Article

References (21)

1. Barkley JE, Green MR: Bronchioloalveolar carcinoma. J Clin Oncol 14:2377-2386, 1996
2. Barsky SH, Grossman DA, Ho J, et al: The multifocality of bronchioloalveolar lung carcinoma: Evidence and implications of a multiclonal origin. Mod Pathol 7:633-640, 1994
3. Travis WD, Lubin J, Reis L, et al: United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females. Cancer 77:2464-2470, 1996
4. West HL, Crowley JJ, Vance RB, et al: Advanced bronchioalveolar carcinoma: A phase II trial trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group trial. Ann Oncol 16: 1076-1080, 2005
5. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
6. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
7. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
8. Gandara DR, West H, Chansky K, et al: Bronchioloalveolar carcinoma: A model for investigating the biology of EGFR Inhibition. Clin Cancer Res 10:4205s-4209s, 2004
9. Hirsch FR, Varella-Garcia M, McCoy J, et al: Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). J Clin Oncol 23:6838-6845, 2005
10. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
11. Sabloff BS, Truong MT, Wistuba II, et al: Bronchioalveolar cell carcinoma: Radiologic appearance and dilemmas in the assessment of response. Clin Lung Cancer 6:108-112, 2004
12. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
13. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
15. Cox DR: Regression models and life tables. J Royal Stat Soc Series B 34:187-202, 1972
16. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004
17. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
18. Franklin WA, Chansky K, Gumerlock PH, et al: Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126). Proc Amer Soc Clin Oncol 23:620s, 2004 (abstr 7015)
19. Hirsch FR, Gandara DR, McCoy J, et al: Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). J Clin Oncol 24:628s, 2005 (abstr 7030)
20. Kris MG, Sandler A, Miller VA, et al: Cigarette smoking history predicts sensitivity to erlotinib (Tarceva): Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc Am Soc Clin Oncol 23: 631s, 2004 (abstr 7062)
21. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005